Abstract 2558: Multi-omic single-cell assessment of castration-resistant prostate cancer patients receiving177Lu-PSMA-617 and pembrolizumab shows timing of radioligand therapy alters immune responseAnusha Muralidhar, Lawrence Fong, Shloka Shukla et al.|Cancer Research|2026Cited by 0